Targeted drug combination therapy design based on driver genes
Lilian Zsákai1,2, Anna Sipos1,3, Judit Dobos1
1Vichem Chemie Research Ltd., Budapest, Hungary.
Abstract:
Targeted therapies against cancer types with more than one driver gene hold bright but elusive promise, since approved drugs are not available for all driver mutations and monotherapies often result in resistance. Targeting multiple driver genes in different pathways at the same time may provide an impact extensive enough to fight resistance. Our goal was to find synergistic drug combinations based on the availability of targeted drugs and their biological activity profiles and created an associated compound library based on driver gene-related protein targets. In this study, we would like to show that driver gene pattern based customized combination therapies are more effective than monotherapies on six cell lines and patient-derived primary cell cultures. We tested 55-102 drug combinations targeting driver genes and driver pathways for each cell line and found 25-85% of these combinations highly synergistic. Blocking 2-5 cancer pathways using only 2-3 targeted drugs was sufficient to reach high rates of tumor cell eradication at remarkably low concentrations. Our results demonstrate that the efficiency of cancer treatment may be significantly improved by combining drugs against multiple tumor specific drivers.
Insights
Targeted cancer therapies combining drugs against multiple driver genes show high effectiveness. Customized combination treatments overcome resistance and improve tumor cell eradication compared to single-drug approaches.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Targeted therapies for cancers with multiple driver genes offer promise but face challenges like drug availability and resistance to monotherapies.
- Simultaneous targeting of multiple driver genes across different pathways may overcome treatment resistance.
Purpose of the Study:
- To identify synergistic drug combinations for cancer treatment based on drug availability and biological activity.
- To evaluate the efficacy of customized, multi-driver gene-targeting combination therapies against cancer cell lines and primary cultures.
Main Methods:
- Created a compound library targeting driver gene-related proteins.
- Tested 55-102 drug combinations per cell line, focusing on driver genes and pathways.
- Assessed synergy and tumor cell eradication rates.
Main Results:
- Found 25-85% of tested drug combinations to be highly synergistic.
- Demonstrated that blocking 2-5 cancer pathways with 2-3 targeted drugs effectively eradicated tumor cells at low concentrations.
- Showed customized combination therapies were more effective than monotherapies in six cell lines and primary cultures.
Conclusions:
- Driver gene pattern-based customized combination therapies significantly enhance cancer treatment efficacy.
- Combining targeted drugs against multiple tumor-specific drivers can improve outcomes and overcome resistance.
- This approach holds potential for more effective cancer treatment strategies.
More Related Videos
12:03Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
08:14Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
Published on: October 26, 2018
Related Concept Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
12:03Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
00:59Gene Therapy
08:14Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
07:40A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
05:09Lumbar Intrathecal Injection of Gene Therapy Vectors for Central Nervous System Targeting in Mice and Rats